Active surveillance has been shown to have the same 10 year survival benefits as surgery or radiotherapy for men with low risk localised prostate cancer, whilst offering the opportunity to delay or avoid these treatments and their potential side effects.
We want all eligible men across the UK to be offered active surveillance to the highest standards, including psychological and emotional support so they can confidently choose this approach and benefit from it for as long as possible.
To achieve this, with the help of our supporters, we have pushed for the latest evidence to be reflected in the NICE (National Institute for Health and Care Excellence) Guideline for prostate cancer diagnosis and management. We have also worked with health professionals, researchers, and people affected by prostate cancer to develop a suite of materials to be used by health professionals, alongside the NICE guidelines to make sure active surveillance is delivered to best practice.